CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
New this year at the CCTG Spring Meeting is an open workshop and education session on engaging patient representatives in CCTG clinical trials. This accredited workshop takes place on Friday 28 at 10:30 in the Wren room at the Chelsea Hotel.
Participants are invited to discuss and assess the Investigator and Patient perspective in patient-centred clinical trials. There will be an exploration of the CCTG Patient Engagement Model and an assessment of the clinical trial lifecycle identifying touch points to engage patients.
Canadian Cancer Society announces details of research funding for low-survival cancers, the CCTG Breakthrough Grant Application lead by Dr Marshall Pitz, has received $ 1,549,130 over 5 years.
The CO29 trial: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Sutdy, AGITG DYNAMIC-III has closed to accrual. The study reached its overall accrual target of 1000 patients, 209 of which were randomized by Canadian sites.
#CCTG2023 is fast approaching and you are running out of time and if you have not register or requested an invitation please do so now!
The inaugural CCTG Award for Excellence in Clinical Trials Conduct will be presented this year at the Recognition Awards at the Annual Spring Meeting of Participants to an individual who exemplifies excellence in clinical trial operations and/or compliance at their institution.
